These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 34634427)

  • 1. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
    Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
    Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect Comparisons.
    Reinisch W; Melmed GY; Nakase H; Seidelin J; Ma C; Xuan S; Tran J; Remple V; Wegrzyn L; Levy G; Sanchez Gonzalez Y; Panaccione R
    Adv Ther; 2024 Oct; 41(10):3832-3849. PubMed ID: 39126596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
    Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
    Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
    Ibing S; Cho JH; Böttinger EP; Ungaro RC
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2629-2638. PubMed ID: 36787837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of ustekinumab in treatment of ulcerative colitis: a narrative review.
    Grova M; Vitello A; Mannino M; Casà A; Renna S; Macaluso FS; Orlando A
    Immunotherapy; 2023 Dec; 15(18):1539-1552. PubMed ID: 38018475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases.
    Cheng D; Kochar BD; Cai T; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2366-2372.e6. PubMed ID: 35066137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Barré A; Colombel JF; Ungaro R
    Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.
    Balderramo D; Yamamoto-Furusho J; Ponce de León E; de María J; Zubiaurre I; Pedreira S; Lis C; Brion L; de Paula JA
    Gastroenterol Hepatol; 2024 Jan; 47(1):51-62. PubMed ID: 37062500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effectiveness and persistence rate of ustekinumab dose intensification in a South East Asian inflammatory bowel disease center.
    Lim CT; Tay SW; Elangovan S; Ong WC; Lim GH; Salazar E; Chan WPW; Tan MTK
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1544-1553. PubMed ID: 38680014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
    Almario CV; Keller MS; Chen M; Lasch K; Ursos L; Shklovskaya J; Melmed GY; Spiegel BMR
    Am J Gastroenterol; 2018 Jan; 113(1):58-71. PubMed ID: 29206816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease.
    Yiu TH; Ko Y; Pudipeddi A; Natale P; Leong RW
    Aliment Pharmacol Ther; 2024 Jun; 59(11):1312-1334. PubMed ID: 38651771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
    Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
    Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases.
    Fabiszewska S; Derda E; Szymanska E; Osiecki M; Kierkus J
    J Clin Med; 2021 Jul; 10(13):. PubMed ID: 34279480
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB.
    Fróes RSB; Andrade AR; Faria MAG; de Souza HSP; Parra RS; Zaltman C; Dos Santos CHM; Bafutto M; Quaresma AB; Santana GO; Luporini RL; de Lima Junior SF; Miszputen SJ; de Souza MM; Herrerias GSP; Junior RLK; do Nascimento CR; Féres O; de Barros JR; Sassaki LY; Saad-Hossne R
    Sci Rep; 2024 Feb; 14(1):4314. PubMed ID: 38383742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?
    Lightner AL; McKenna NP; Alsughayer A; Harmsen WS; Taparra K; Parker ME; Raffals LE; Loftus EV
    Dis Colon Rectum; 2019 Nov; 62(11):1352-1362. PubMed ID: 31567927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature.
    Berinstein EM; Sheehan JL; Jacob J; Steiner CA; Stidham RW; Shannon C; Bishu S; Levine J; Cohen-Mekelburg SA; Waljee AK; Higgins PDR; Berinstein JA
    Dig Dis Sci; 2023 Jun; 68(6):2604-2623. PubMed ID: 36807832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
    Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
    Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab Does Not Increase Risk of Adverse Events: A Meta-Analysis of Randomized Controlled Trials.
    Rolston VS; Kimmel J; Popov V; Bosworth BP; Hudesman D; Malter LB; Hong S; Chang S
    Dig Dis Sci; 2021 May; 66(5):1631-1638. PubMed ID: 32445049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?
    Tepeš K; Hanžel J; Štubljar D; Strmšek K; Erjavec L; Supovec E; Jagodic Z; Končan M; Grosek J; Košir JA; Tomažič A; Kogovšek U; Norčič G; Šibli R; Žnidaršič M; Pačnik Vižintin T; Sodin B; Breznik J; Hribar VA; Ocepek A; Pernat Drobež C; Bukovnik N; Zafošnik A; Marušič T; Jurečič Brglez N; Denkovski M; Smrekar N; Novak G; Koželj M; Kurent T; Simonič J; Pintar Š; Štabuc B; Drobne D
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):728-734. PubMed ID: 38625825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms.
    Mocci G; Tursi A; Onidi FM; Usai-Satta P; Pes GM; Dore MP
    J Clin Med; 2024 Mar; 13(5):. PubMed ID: 38592377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.